179 related articles for article (PubMed ID: 12888170)
1. [Rituximab in cold agglutinin disease].
Camou F; Viallard JF; Pellegrin JL
Rev Med Interne; 2003 Aug; 24(8):501-4. PubMed ID: 12888170
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
3. [Efficacity of rituximab in hemolytic anemia with cold autoantibodies case].
Sekkach Y; Hammi S; Elqatni M; Fatihi J; Elomri N; Mekouar F; Badaoui M; Jira M; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
Ann Pharm Fr; 2011 Jul; 69(4):205-8. PubMed ID: 21840439
[TBL] [Abstract][Full Text] [Related]
4. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.
Berentsen S; Tjønnfjord GE; Brudevold R; Gjertsen BT; Langholm R; Løkkevik E; Sørbø JH; Ulvestad E
Br J Haematol; 2001 Oct; 115(1):79-83. PubMed ID: 11722415
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma.
Cohen Y; Polliack A; Zelig O; Goldfarb A
Leuk Lymphoma; 2001; 42(6):1405-8. PubMed ID: 11911426
[TBL] [Abstract][Full Text] [Related]
6. [Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease.
Vassou A; Alymara V; Chaidos A; Bourantas KL
Int J Hematol; 2005 Jun; 81(5):421-3. PubMed ID: 16158824
[TBL] [Abstract][Full Text] [Related]
8. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
Jourdan E; Topart D; Richard B; Jourdan J; Sotto A
Leuk Lymphoma; 2003 May; 44(5):889-90. PubMed ID: 12802933
[TBL] [Abstract][Full Text] [Related]
9. Remission of severe cold agglutinin disease after Rituximab therapy.
Layios N; Van Den Neste E; Jost E; Deneys V; Scheiff JM; Ferrant A
Leukemia; 2001 Jan; 15(1):187-8. PubMed ID: 11243390
[No Abstract] [Full Text] [Related]
10. Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment.
Morselli M; Luppi M; Potenza L; Tonelli S; Dini D; Leonardi G; Donelli A; Narni F; Torelli G
Blood; 2002 May; 99(9):3478-9. PubMed ID: 12001903
[No Abstract] [Full Text] [Related]
11. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.
Mori A; Tamaru J; Sumi H; Kondo H
Eur J Haematol; 2002 Apr; 68(4):243-6. PubMed ID: 12071942
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus.
Kotani T; Takeuchi T; Kawasaki Y; Hirano S; Tabushi Y; Kagitani M; Makino S; Hanafusa T
Lupus; 2006; 15(10):683-5. PubMed ID: 17120596
[TBL] [Abstract][Full Text] [Related]
14. [Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune hemolytic anemia].
Wang L; Xu W; Li JY; Xie XY; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):425-8. PubMed ID: 17493362
[TBL] [Abstract][Full Text] [Related]
15. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.
Berentsen S; Beiske K; Tjønnfjord GE
Hematology; 2007 Oct; 12(5):361-70. PubMed ID: 17891600
[TBL] [Abstract][Full Text] [Related]
16. Severe hemolytic anemia due to cold agglutinin complicating untreated chronic hepatitis C: efficacy and safety of anti-CD20 (rituximab) treatment.
Etienne A; Gayet S; Vidal F; Poullin P; Brunet C; Harlé JR; Kaplanski G
Am J Hematol; 2004 Apr; 75(4):243-5. PubMed ID: 15054819
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
18. Treatment of childhood autoimmune haemolytic anaemia with rituximab.
Quartier P; Brethon B; Philippet P; Landman-Parker J; Le Deist F; Fischer A
Lancet; 2001 Nov; 358(9292):1511-3. PubMed ID: 11705566
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune hemolytic anemia with giant cell hepatitis: case report and review of the literature.
Gorelik M; Debski R; Frangoul H
J Pediatr Hematol Oncol; 2004 Dec; 26(12):837-9. PubMed ID: 15591908
[TBL] [Abstract][Full Text] [Related]
20. Success of anti-CD20 monoclonal antibody treatment for severe autoimmune hemolytic anemia caused by warm-reactive immunoglobulin A, immunoglobulin G, and immunoglobulin M autoantibodies in a child: a case report.
Ajmi H; Mabrouk S; Hassayoun S; Regaieg H; Tfifha M; Jalel C; Skouri H; Zouari N; Abroug S
J Med Case Rep; 2017 Nov; 11(1):321. PubMed ID: 29132419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
